SCHEMBL1484730

SCHEMBL1484730

CSC(=N)NC(=O)OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
POLB P06746 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
CYP2C9 P11712 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 2/20 0.46
TSHR P16473 2/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM1A O60341 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15180278 0.84 SMN1; SMN2 (0.53) ALDH1A1POLBNPC1RAB9ALMNA
SCHEMBL16945695 0.82 ALDH1A1 (0.59) ALDH1A1POLBNPC1RAB9ALMNA
SCHEMBL13933398 0.82 LMNA (0.54) ALDH1A1POLBNPC1RAB9ALMNA
SCHEMBL2321117 0.82 LMNA (0.56) ALDH1A1POLBNPC1RAB9ALMNA
SCHEMBL13615353 0.81 MAPT (0.44) ALDH1A1POLBNPC1RAB9ALMNA
SCHEMBL234454 0.81 LMNA (0.62) ALDH1A1POLBNPC1RAB9ALMNA
SCHEMBL5969412 0.81 ALDH1A1 (0.53) ALDH1A1POLBNPC1RAB9ALMNA
Iodide SCHEMBL3822935 0.81 CTSL (0.54) ALDH1A1POLBNPC1RAB9ALMNA
SCHEMBL18620840 0.79 ALDH1A1 (0.51) ALDH1A1POLBNPC1RAB9ALMNA
SCHEMBL1763734 0.79 LMNA (0.57) ALDH1A1POLBNPC1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024032799-A1 Preparation Method of Tetrodotoxin and its Analog NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2024-02-15 WO disclosed
US-20220386611-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2022-12-08 US disclosed
WO-2021069569-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2021-04-15 WO disclosed
EP-2483277-B1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE HOFFMANN LA ROCHE (CH) 2015-12-02 EP disclosed
CN-102762574-B Benzoxapi 3K inhibitor compounds and methods of use HOFFMAN-LA ROCHE LTD. (CH) 2015-12-02 CN disclosed
US-9175009-B2 Benzoxepin PI3K inhibitor compounds and methods of use GENENTECH, INC. (US) 2015-11-03 US disclosed
CN-104987345-A BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE HOFFMANN LA ROCHE 2015-10-21 CN disclosed
US-20150094347-A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2015-04-02 US disclosed
US-8952043-B2 Benzoxepin PI3K inhibitor compounds and methods of use GENETECH, INC. (US) 2015-02-10 US disclosed
EP-2784078-A1 Benzoxepin pi3k inhibitor compounds and methods of use F. Hoffmann-La Roche AG (CH) 2014-10-01 EP disclosed
WO-1996037497-A1 LOW MOLECULAR WEIGHT BICYCLIC-UREA TYPE THROMBIN INHIBITORS BIOCHEM PHARMA INC. (CA) 1996-11-28 WO disclosed
CN-1134696-A Substituted 5-membered heterocycles, process for their preparation and their use CASSELLA FARBWERKE MAINKUR AG (DE) 1996-10-30 CN disclosed
CN-1127509-A Novel peptide derivatives ASTRA AB (SE) 1996-07-24 CN disclosed
EP-0701568-A1 NEW PEPTIDE DERIVATIVES Astra Aktiebolag (SE) 1996-03-20 EP disclosed
EP-0701550-A1 PROCESS FOR THE PRODUCTION OF AMINOALKYLGUANIDINES Astra Aktiebolag (SE) 1996-03-20 EP disclosed
US-5498724-A Pyrazoleamidine compounds AKTIEBOLAGET ASTRA (SE) 1996-03-12 US disclosed
CN-1099759-A Piperazine derivatives MERCK PATENT GMBH (DE) 1995-03-08 CN disclosed
WO-1994029336-A1 NEW PEPTIDE DERIVATIVES ASTRA AKTIEBOLAG (SE) 1994-12-22 WO disclosed
WO-1994029269-A1 PROCESS FOR THE PRODUCTION OF AMINOALKYLGUANIDINES ASTRA AKTIEBOLAG (SE) 1994-12-22 WO disclosed
US-4346078-A Novel anticoagulant agmatine derivatives and process for the preparation thereof RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1982-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150094347-A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE BMX, NR2E1, NR2E3 ALDH1A1 4809/4885POLB 3392/4885NPC1 894/4885
US-20220386611-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES GLRX3, CYP4X1, CYP4F3 ALDH1A1 4092/4885POLB 4683/4885NPC1 4034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.